Neuroscientists and neurosurgeons at the EPFL/CHUV/UNIL, Inserm and the University of Bordeaux have designed a neuroprosthetic intended to correct walking disorders associated with Parkinson’s disease.
Researchers at the CHUV and Inserm studied the risk of cardiovascular events related to sleep disorders. This study shows that five components of sleep have a significant impact on the risk of coronary events and strokes.
Neuroscientists and neurosurgeons from EPFL/CHUV/UNIL and CEA/CHUGA/UGA report that they have re-established the communication between the brain and spinal cord with a wireless digital bridge, allowing a paralyzed person to walk again naturally.
The neuro-oncology team at the CHUV is intensely involved in international and in-house clinical trials. Clinical trials represent an important opportunity for patients who can potentially benefit from the latest advances in the field.
A system developed by Grégoire Courtine and Jocelyne Bloch now enables patients with a complete spinal cord injury to stand, walk and even perform recreational activities like swimming, cycling and canoeing.
At our Center for Sleep Investigation and Research, Professor Francesca Siclari has been awarded two grants between 2021 and 2022, including a prestigious ERC Starting Grant, for her research on mechanisms at the origin of dreams.
The “Collaborative Outcomes Study on Health and Functioning during Infection Times” (COH-FIT), which involves almost 200 researchers from over 40 countries on six continents, aims to measure the impact of the COVID-19 on physical and mental health.
Supported by the SNF, this research project is based on the hypotheses that severe presentation of COVID-19 results from genetic predisposition and that transcriptomic profiling at an early stage may help predict adverse outcomes.
As part of the “Corona Accelerated R&D in Europe” (CARE) programme, the Allergy and Immunology Department at CHUV has secured funding of almost 5 million Swiss francs for its work aimed at isolating antibodies that neutralise the coronavirus.
Supported by the Swiss National Science Foundation (NSF) and in collaboration with the Federal Office of Public Health (FOPH), CHUV is coordinating Switzerland’s participation in the “Solidarity” study.
In conjunction with the École polytechnique fédérale de Lausanne (EPFL) and the Swiss Vaccine Research Institute (SVRI), CHUV has developed the blood test selected for conducting population studies in Switzerland.
To fight lymphoblastic leukaemia in children and young adults, the UNIL CHUV Oncology Department and our paediatric oncology consultation have developed an innovative immunotherapy in collaboration with Seattle Children's Hospital.
The CoLaus|PsyCoLaus study includes more than 6,700 inhabitants of the city of Lausanne in Switzerland followed for over 15 years. The results of the study have already given rise to more than 470 publications.